Cargando…

EU Clinical trial regulation in the environment of rare diseases: time for a change

Detalles Bibliográficos
Autor principal:	Zimmermann, Martine
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958408/ http://dx.doi.org/10.1186/1750-1172-5-S1-P19

Ejemplares similares

Clinical trials in rare diseases: a review of practice
por: Bell, Stuart, et al.
Publicado: (2013)

http://www.euro-wabb.org: an EU Register for Alstrom, Bardet Biedl and other rare syndromes
por: Barrett, T, et al.
Publicado: (2012)

Clinical development of nitisinone for alkaptonuria (developakure) - a rare disease clinical trials design
por: Psarelli, Eftychia Eirini, et al.
Publicado: (2013)

The paediatric hepatic international tumour trial (PHITT): clinical trial design in rare disease
por: Moroz, Veronica, et al.
Publicado: (2015)

A multinational, drug utilisation study to investigate the use of dexmedetomidine (DEXDOR®) in clinical practice in the EU
por: Garratt, C, et al.
Publicado: (2015)

Orphandev, French Clinical Trials Network dedicated to Orphan drugs and therapeutics development for rare diseases
por: Adjibi, Yolande, et al.
Publicado: (2010)

Comparing the use of traditional and agile development methodologies in a clinical trials environment
por: Rauchenberger, Mary, et al.
Publicado: (2013)

P02-17 Promoting physical activity for mental health in the EU: Development and implementation of practice guidelines from the SPHERE EU project 2019-2020
por: Crone, Diane, et al.
Publicado: (2022)

Flexible trial design in a rare condition
por: Moroz, Veronica, et al.
Publicado: (2013)

The implementation in Europe (EU) of the low risk drinking guidelines: results from the RARHA survey
por: Scafato, Emanuele, et al.
Publicado: (2015)

Recruitment into trials of rare conditions - experiences from the STOP GAP trial
Publicado: (2011)

Zygomycosis by Rhizopus species – a very rare angioinvasive mycosis: report of three cases
por: Lewejohann, J, et al.
Publicado: (2005)

The use of Bayesian design in two trials in rare cancers
por: Dutton, Peter, et al.
Publicado: (2015)

Serial changes in ICU-acquired pneumonia pathogen after the remodeling of the environment in a MICU
por: Hong, S, et al.
Publicado: (2005)

Phosphocreatine recovery time constant (PCr) at peak exercise as a potential endpoint for clinical trials in PAD
por: Gonzalez, Jorge A, et al.
Publicado: (2016)

Impact of training for site staff recruiting into trials of rare skin diseases: experiences from stop gap and blister
por: Mitchell, Eleanor, et al.
Publicado: (2013)

The use of historical priors to improve the efficiency of phase II clinical trials with time-to-event endpoints
por: Jackson, Richard, et al.
Publicado: (2013)

Exploring the Impact of health-care cost sharing mechanisms in health service users for all the 27 member countries of the EU
por: Siakou, Andreas, et al.
Publicado: (2015)

Integration of Rare Diseases into Social Services
por: Castro, Raquel, et al.
Publicado: (2014)

Time to be brave: is educating surgeons the key to unlocking the potential of randomized clinical trials in surgery? A qualitative study
por: Potter, Shelley, et al.
Publicado: (2013)

Outcomes to measure patient safety: the patient reporting and action for a safe environment (PRASE) trial
por: Buckley, Hannah, et al.
Publicado: (2015)

Relationships between irregular work arrangements and occupational injuries in EU 27. Findings from the fifth European working condition survey
por: Alali, Hanan, et al.
Publicado: (2015)

National rare diseases registry in Spain: pilot study of the Spanish Rare Diseases Registries Research Network (SpainRDR)
por: Alonso, Verónica, et al.
Publicado: (2014)

31. Takayasu arteritis presenting as bilateral popliteal artery aneurysm: a rare presentation of a rare disease
por: Abdulkarim, Saadeya, et al.
Publicado: (2019)

Change in timed walk as primary outcome measure of treatment response in HAMLET-P: HAM/TSP MuLticentre Efficacy trial-Prednisolone
por: Martin, Fabiola, et al.
Publicado: (2014)

Standard X-rays for the victims of severe trauma: time for a change
por: Cingolani, E, et al.
Publicado: (2010)

P132 Research in the time of COVID-19: Recruitment to a clinical trial comparing models of NIV implementation in people with MND
por: Sheers, N, et al.
Publicado: (2021)

COST Action FP0905: Biosafety of forest transgenic trees: improving the scientific basis for safe tree development and implementation of EU policy directives
por: Vettori, Crstina, et al.
Publicado: (2011)

Behçet disease – although rare can be present in children
por: Stancu, Aurelia
Publicado: (2014)

Se-atlas-cartographic representation of experts for rare diseases
por: Storf, Holger, et al.
Publicado: (2014)

Ultrasound measurement of carotid flow time changes with volume status
por: Mackenzie, DC, et al.
Publicado: (2014)

Temperature-induced changes of spike timing precision and network synchronisation
por: Schleimer, Jan-Hendrik, et al.
Publicado: (2015)

Update on policy change proposal to end Institutional Biosafety Committee (IBC) review of rDNA vaccine clinical trials
por: Enama, ME, et al.
Publicado: (2012)

The implementation in Europe (EU) of the drinking guidelines for the Early Identification and Brief Interventions (EIBI) for Hazardous and Harmful Alcohol Consumption (HHAC): results from the RARHA survey
por: Scafato, Emanuele, et al.
Publicado: (2015)

Psychological aspects of living with rare disease: development of psychological skills of rare disease patients. How to improve patients’ quality of life by developing psychological skills necessary to cope with the disease
por: Wierzba, Yolanta, et al.
Publicado: (2010)

European Project for Rare Diseases National Plans Development (EUROPLAN)
por: Taruscio, Domenica, et al.
Publicado: (2010)

PB.24. How does volumetric breast density change with time?
por: Daniels, J, et al.
Publicado: (2014)

Impact of hereditary periodic fever syndromes and its change over time
por: Niewerth, M, et al.
Publicado: (2015)

Natural environment promotes deeper brain functional connectivity than built environment
por: Chen, Zheng, et al.
Publicado: (2015)

Creating a supportive environment is very important to reduce STI, HIV/AIDS and infectious disease
por: Islam, SM Rezaul
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_pi6rgoqhu4n78fdmgcj5fbqrq5